Blood Sugar: The Number That’s Quietly Deciding Your Future

What high blood sugar actually does to your body, what the tests really tell us, and what you can do about it — starting at your next annual physical.

By the Numbers

38 million	Americans living with diabetes
96 million	Americans with prediabetes — 80% don’t know it
$412 billion	Annual cost of diagnosed diabetes in the U.S.
80%	Of type 2 diabetes cases preventable with lifestyle change

What Is Blood Sugar, Actually?

Every time you eat, your digestive system breaks carbohydrates down into glucose — the body’s primary fuel source. That glucose enters your bloodstream, triggering the pancreas to release insulin. Insulin acts like a key that unlocks your cells, allowing glucose to move out of the blood and into tissues where it’s used for energy.

When this system works well, blood sugar rises after meals and returns to baseline within a couple of hours. When it doesn’t — whether because the pancreas isn’t producing enough insulin, because cells have stopped responding to it properly, or both — glucose builds up in the bloodstream. That’s hyperglycemia. And chronically elevated blood sugar, even at levels that cause no symptoms, is one of the most damaging forces in the human body.

The damage is cumulative and largely invisible. Over years, excess glucose acts like sandpaper on the inside of blood vessels — stiffening artery walls, promoting inflammation, and accelerating the kind of vascular damage that eventually shows up as heart attack, stroke, kidney failure, vision loss, and nerve damage. Diabetes is the leading cause of new-onset blindness in working-age adults, the leading cause of non-traumatic lower-limb amputation, and a major driver of kidney disease requiring dialysis. These outcomes don’t happen suddenly. They develop quietly, over a decade or more, while blood sugar stays high and symptoms stay absent.

This is why we check your blood sugar at your annual visit — and why we don’t stop at a single number. Early detection changes outcomes. The annual physical is the single most reliable opportunity to find a problem before it becomes a crisis.

The Numbers: What Do They Mean?

A single fasting glucose test tells you what your blood sugar is doing right now, after an overnight fast. That’s useful, but it’s incomplete. Blood sugar fluctuates throughout the day and across weeks. A snapshot can look fine on a morning when your body happened to perform well. At Altitude, we believe in using the full panel of available tools to build a more complete picture — because the earlier we identify a problem, the more options you have.

Here are the tests we use and what each one tells us:

Fasting Glucose measures blood sugar after an 8-hour fast. It’s the standard screening test and is included in a basic metabolic panel. A fasting glucose of 100 or higher warrants attention, even if it doesn’t meet the threshold for prediabetes — trends matter as much as single values.

Hemoglobin A1C (HbA1c) reflects your average blood sugar over the past two to three months by measuring how much glucose has attached to red blood cells. It doesn’t require fasting, is highly reproducible, and is the preferred diagnostic and monitoring test for most people. Critically, A1C can identify impaired glucose metabolism even when a single fasting glucose looks normal. We routinely check A1C at annual physicals for adults over 35, anyone with risk factors, and anyone with a fasting glucose trending upward — not just those already diagnosed.

Fasting Insulin is not part of standard screening panels, but it’s one of the most informative tests we can run. Insulin levels rise years — sometimes a decade — before glucose does, as the pancreas works overtime to compensate for early insulin resistance. A person with a normal fasting glucose and a high fasting insulin is already on a metabolic trajectory toward prediabetes. This test gives us the earliest possible warning. We use it selectively in patients with risk factors, weight gain, or metabolic symptoms where standard tests may not yet be abnormal.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is calculated from fasting glucose and fasting insulin together. It quantifies how insulin-resistant your tissues are, giving us a number that correlates with cardiovascular and metabolic risk even in people whose glucose hasn’t crossed any diagnostic threshold.

Urine Microalbumin-to-Creatinine Ratio detects tiny amounts of protein leaking into the urine — one of the earliest signs of kidney damage from elevated blood sugar or blood pressure. Annual urine testing is standard care for anyone with diabetes, but it’s also informative in people with risk factors before a diagnosis is ever made.

Fasting Lipid Panel is directly relevant to blood sugar because insulin resistance dramatically distorts cholesterol patterns — typically raising triglycerides and lowering HDL, even when total cholesterol looks acceptable. A triglyceride-to-HDL ratio above 3.0 is a meaningful marker of insulin resistance and cardiovascular risk that a basic glucose test will miss entirely.

Here’s how the primary diagnostic thresholds break down:

Category	Fasting Glucose	A1C
✅ Normal	Below 100 mg/dL	Below 5.7%
⚠️ Prediabetes	100–125 mg/dL	5.7–6.4%
🔴 Diabetes	126 mg/dL or higher	6.5% or higher
🎯 Treatment Target (most adults with diabetes)	80–130 mg/dL (pre-meal)	Below 7.0%

These thresholds are population averages. Your personal target may differ based on age, other health conditions, and medication regimen — exactly the kind of conversation to have at your annual physical.

The goal of testing more broadly isn’t to alarm people. It’s to give us enough information to intervene at the earliest possible moment — when lifestyle changes are most powerful, when the biology is most reversible, and when we can prevent a decade of quiet damage before it becomes something harder to treat.

Prediabetes: The Window You Don’t Want to Miss

Nearly 96 million Americans — one in three adults — have prediabetes. Eighty percent of them don’t know it, because prediabetes has no symptoms and most people haven’t been tested comprehensively. Prediabetes means your blood sugar is elevated but not yet high enough to qualify as type 2 diabetes. It also means your body’s insulin response is already under significant strain.

This is the most important moment to intervene — not after a diabetes diagnosis, but before one. The Diabetes Prevention Program, one of the landmark clinical trials in preventive medicine, showed that structured lifestyle intervention (modest weight loss, dietary change, 150 minutes of weekly activity) reduced progression from prediabetes to type 2 diabetes by 58%. In adults over 60, that number was 71%. Metformin reduced progression by 31% — effective, but substantially less so than lifestyle.

The window is real. The biology is genuinely reversible at this stage in a way it isn’t later. But you can’t act on a problem you don’t know you have. This is the argument for comprehensive screening at every annual physical — not waiting for symptoms, not waiting for a glucose that crosses a threshold, but looking actively and early.

If your fasting glucose or A1C falls in the prediabetes range, this isn’t a warning to file away. It’s a call to act.

Type 1 vs. Type 2: Not the Same Disease

These share a name but have different causes and different trajectories.

Type 1 diabetes is an autoimmune condition in which the immune system destroys the insulin-producing beta cells of the pancreas. It typically presents in childhood or early adulthood, though it can occur at any age. People with type 1 produce little to no insulin and require insulin replacement to survive. It is not caused by diet or lifestyle.

Type 2 diabetes develops when cells throughout the body become progressively resistant to insulin’s effects, and the pancreas eventually can no longer compensate with increased output. It accounts for roughly 90–95% of all diabetes cases. Genetics matter, but the condition is heavily shaped by lifestyle, body weight, physical activity, diet quality, and sleep. It is largely — though not entirely — preventable.

Gestational diabetes develops during pregnancy and resolves in most cases after delivery, but carries a significantly elevated lifetime risk of type 2 diabetes for both mother and child.

There is also LADA (Latent Autoimmune Diabetes in Adults), sometimes called type 1.5, which shares features of both and is frequently misdiagnosed as type 2. Fasting insulin and C-peptide testing can help distinguish these when the diagnosis is uncertain.

Why “I Feel Fine” Doesn’t Mean You’re Fine

Early hyperglycemia has no symptoms. None that are obvious, anyway. By the time classic symptoms appear — increased thirst, frequent urination, fatigue, blurry vision, slow-healing wounds — blood sugar has typically been elevated for years.

This is not a minor detail. The vascular and neural damage that drives diabetes complications begins accumulating at blood sugar levels that feel completely normal. Studies consistently show that a significant portion of people newly diagnosed with type 2 diabetes already have early-stage complications at the time of diagnosis. That damage didn’t develop overnight.

When symptoms do appear, the most common early ones are:

• Increased thirst and frequent urination (the kidneys working overtime to filter excess glucose)
• Fatigue and difficulty concentrating
• Blurred vision (the lens of the eye swells with fluid as blood sugar rises)
• Tingling or numbness in the hands or feet (early neuropathy)
• Slow-healing cuts or frequent infections
• Unexplained weight loss (in type 1 and late-stage type 2, when cells can’t access glucose for fuel)

Many people attribute these symptoms to aging, stress, or poor sleep — and dismiss them. If any of these sound familiar, they’re worth mentioning at your next visit.

“The absence of symptoms is not reassurance. Diabetes does its most dangerous work silently, across a decade, before it ever announces itself.”

What Drives Blood Sugar Up

Understanding what elevates blood sugar matters because most of these factors are modifiable:

Refined carbohydrates and added sugar. Foods that digest quickly — white bread, sugary drinks, pastries, white rice — produce rapid spikes in blood glucose. The total amount of carbohydrate matters, but so does the type.

Body weight. Excess body fat, particularly visceral fat around the abdomen, drives insulin resistance. This is the central mechanism of type 2 diabetes for most people. Even modest weight loss — 5 to 10% of body weight — meaningfully improves insulin sensitivity.

Physical inactivity. Skeletal muscle is the primary site of glucose uptake in the body. Movement — especially after meals — significantly improves glucose clearance. Sitting for extended periods has independent negative effects on insulin sensitivity, even in people who exercise regularly.

Sleep deprivation and poor sleep quality. A single night of poor sleep measurably impairs insulin sensitivity. Chronic sleep deprivation is a meaningful driver of metabolic dysfunction. Untreated sleep apnea is particularly problematic.

Chronic stress. Cortisol raises blood sugar directly. Chronic psychological stress maintains cortisol elevation, and stress-related eating compounds the effect.

Certain medications. Corticosteroids, some antipsychotics, and several other drug classes raise blood sugar. This is worth discussing with your provider if you’re on long-term medication.

Genetics. Having a first-degree relative with type 2 diabetes significantly increases your risk. Genetics set the playing field; lifestyle determines how the game is played.

Complications: What’s Really at Stake

This is the section worth reading carefully. The risks of chronically elevated blood sugar extend well beyond what most people expect — and several of them are significantly underappreciated.

Heart Disease and Stroke

Adults with diabetes are two to four times more likely to die from cardiovascular disease than adults without it. Heart disease is the leading cause of death in people with type 2 diabetes, accounting for roughly 50% of all mortality. Hyperglycemia damages arterial walls directly, promotes atherosclerotic plaque formation, raises inflammatory markers, and accelerates the same processes that cause heart attacks and strokes. This isn’t a distant risk — it’s the primary one.

Kidney Disease

Diabetes is the leading cause of kidney failure in the United States, responsible for roughly 40% of all new cases requiring dialysis. Persistent hyperglycemia damages the glomeruli — the tiny filtration units in the kidney — long before kidney function shows up as abnormal on standard blood tests. By the time creatinine rises on a basic metabolic panel, significant damage has typically already occurred. This is one reason we check urine microalbumin annually — it detects kidney involvement a decade earlier than blood tests do.

Weight Gain and the Metabolic Trap

High blood sugar and excess weight have a bidirectional relationship that becomes self-reinforcing. Insulin resistance promotes fat storage, particularly visceral (abdominal) fat. That visceral fat produces inflammatory signals that worsen insulin resistance further. Elevated insulin — which rises early in the course of type 2 diabetes — directly inhibits fat breakdown and promotes fat storage. Many people with prediabetes or early type 2 diabetes find it genuinely difficult to lose weight not because of willpower, but because of the hormonal environment created by insulin resistance. Addressing blood sugar and insulin levels is often the prerequisite to making weight management possible, not just an afterthought to it.

Vision Loss

Diabetic retinopathy is the leading cause of new blindness in working-age adults in the United States. Elevated blood sugar damages the small blood vessels of the retina; over time, those vessels leak, swell, or grow abnormally. Vision loss at this stage can be rapid and irreversible. Annual dilated eye exams are a non-negotiable part of diabetes management — and like most complications, retinopathy is largely preventable with early detection and glucose control.

Nerve Damage (Neuropathy)

Diabetic neuropathy most commonly affects the feet and legs, causing pain, burning, tingling, and numbness. As sensation decreases, minor foot injuries go unnoticed, fail to heal, become infected, and — in severe cases — lead to amputation. Diabetes accounts for the majority of non-traumatic lower-limb amputations in the U.S. Neuropathy can also affect the autonomic nervous system, causing digestive problems, bladder dysfunction, sexual dysfunction, and abnormal heart rate responses. These complications are rarely discussed and frequently underdiagnosed.

Cancer

This is the complication that surprises most people. Chronically elevated blood sugar and insulin resistance are associated with significantly increased risk of several cancers — including colorectal, pancreatic, breast, endometrial, liver, and bladder cancers. The mechanisms are multiple: hyperinsulinemia promotes tumor cell growth; chronic inflammation creates a permissive environment for cancer development; excess glucose provides fuel for rapidly proliferating cells. A 2023 meta-analysis found that people with type 2 diabetes have approximately a 20–25% higher overall cancer incidence than those without it. This is not a rare or marginal risk.

Cognitive Decline and Dementia

Alzheimer’s disease is increasingly understood as having significant vascular and metabolic components. Some researchers now refer to it as “type 3 diabetes” — a term that captures the relationship between insulin resistance in the brain and neurodegeneration. People with type 2 diabetes have roughly a 50–65% higher risk of developing Alzheimer’s disease and a 100–150% higher risk of vascular dementia. The damage mechanism is similar to what happens in the heart and kidney: chronic hyperglycemia injures small blood vessels in the brain, impairs the brain’s ability to use glucose for energy, and promotes the inflammatory and amyloid processes associated with cognitive decline. Controlling blood sugar in your 40s and 50s is not just about protecting your cardiovascular system now — it’s about protecting your mind in your 70s and 80s.

Infections and Immune Function

Elevated blood sugar impairs the function of white blood cells, compromises the skin barrier, reduces blood flow to peripheral tissues, and creates a high-glucose environment that bacteria and fungi thrive in. People with poorly controlled diabetes have higher rates of skin infections, urinary tract infections, pneumonia, and post-surgical complications. During the COVID-19 pandemic, diabetes was among the strongest predictors of severe illness and death — a pattern consistent with how hyperglycemia degrades immune resilience across the board.

These complications share a common thread: they are largely preventable with early detection, consistent management, and the right partnership with your care team. None of them are inevitable. But they do require attention — and that attention starts with knowing your numbers.

The 2025 Guidelines: What’s New

The American Diabetes Association updates its Standards of Care annually. Key 2025 developments include:

GLP-1 receptor agonists moved up the priority list. Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are now recommended early in treatment — not just for blood sugar control, but for their substantial cardiovascular, renal protective, and weight loss effects. For people with type 2 diabetes who also have heart disease, heart failure, or chronic kidney disease, these agents are the preferred first or second-line choice after metformin.

Weight management is now framed as primary treatment. The 2025 guidelines explicitly position sustained weight loss — through lifestyle, medication, or bariatric surgery — as a core therapeutic strategy, not an optional lifestyle add-on. The connection between metabolic health and glucose control is now front and center.

Individualized A1C targets. A target of below 7.0% remains appropriate for most adults, but the guidelines emphasize individualization: less stringent targets (7.0–8.0%) for older adults or those with significant hypoglycemia risk; tighter targets (below 6.5%) for younger patients earlier in their disease course.

Continuous glucose monitoring expanded. CGM is now recommended for all people with diabetes on insulin and encouraged for a broader population. Real-time glucose data changes behavior in ways that periodic A1C checks alone cannot.

Cardiorenal protection prioritized. SGLT2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 agonists now carry formal class-level recommendations for people with type 2 diabetes and cardiovascular disease, regardless of baseline A1C.

Treatment: What the Options Actually Look Like

Diabetes management is not one-size-fits-all. The right regimen depends on what type of diabetes you have, how long you’ve had it, what other conditions are present, and what your personal goals and preferences are.

Lifestyle intervention remains the foundation at every stage. Dietary quality, physical activity, weight management, sleep, and stress are not soft recommendations — they are first-line treatment with strong evidence behind them.

Metformin remains the preferred initial medication for most people with type 2 diabetes who aren’t already on a GLP-1 or SGLT2 agent. It’s inexpensive, well-tolerated, has decades of safety data, and carries modest protective benefits beyond glucose control.

GLP-1 receptor agonists (semaglutide, tirzepatide, dulaglutide) lower blood sugar, promote significant weight loss, reduce cardiovascular events, and protect kidney function. For many patients — particularly those with heart or kidney disease, or those struggling with weight — they are now the preferred second agent or, in some cases, first-line choice.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) lower blood sugar by causing the kidneys to excrete excess glucose. They also reduce heart failure hospitalizations and slow kidney disease progression — benefits that are largely independent of glucose lowering.

Insulin remains essential for all people with type 1 diabetes and for many with type 2 when other agents are insufficient. Modern insulin formulations and delivery systems — including pumps and hybrid closed-loop systems — have dramatically improved manageability.

A medication conversation from two years ago may not reflect what’s available now. The field has moved significantly, and if your regimen hasn’t been reviewed at a recent annual physical, it may be worth revisiting.

Monitoring: What You Can Do at Home

Blood sugar management doesn’t live only in clinic visits. Understanding your numbers between appointments is one of the most empowering things you can do.

Home blood glucose monitoring with a glucometer remains practical and inexpensive. For most people with type 2 diabetes not on insulin, checking fasting glucose and occasionally post-meal glucose provides meaningful real-world feedback.

Continuous glucose monitoring (CGM) devices like the Dexcom G7, Libre 3, or Stelo provide real-time readings every few minutes without finger sticks. Increasingly available to people with both type 1 and type 2 diabetes, CGM reveals patterns that intermittent checks miss — post-meal spikes, overnight trends, and the direct effects of specific foods and activities. This kind of feedback loop accelerates behavior change in a way that a quarterly A1C alone cannot.

What you eat for dinner tonight affects your fasting glucose tomorrow. What you do after lunch affects your afternoon reading. This is not abstract biology — it’s cause and effect you can observe, track, and change.

The Annual Physical: Your Most Important Blood Sugar Appointment

Most of the harm that comes from elevated blood sugar is preventable. But prevention requires knowing where you stand — and that means testing comprehensively, not just once, and not just when symptoms appear.

At your annual physical at Altitude, we don’t stop at a single fasting glucose. Depending on your age, weight, family history, and existing risk factors, we may check:

• A1C to capture average glucose over 2–3 months, even when fasting glucose is normal
• Fasting insulin and HOMA-IR to detect insulin resistance years before glucose becomes abnormal
• Urine microalbumin to catch early kidney involvement at the earliest treatable stage
• A full lipid panel to identify the triglyceride and HDL pattern that marks insulin resistance
• Blood pressure — because high blood pressure and elevated blood sugar compound each other’s damage profoundly

This approach reflects a core belief: a number that looks borderline normal today deserves attention, not a “we’ll check it again next year” and a handshake. Trends matter. The earlier we see a problem developing, the more tools we have to address it — and the less damage accumulates while we wait.

If it’s been more than a year since your last physical, or if you’ve never had a comprehensive metabolic workup, the annual physical is where that starts. Schedule yours at Altitude Family Medicine today.

What You Can Do Starting Today

• Get your blood sugar checked comprehensively. A fasting glucose alone isn’t enough. Ask about A1C and fasting insulin, especially if you have risk factors or your glucose has been trending up. Your annual physical is the right time.
• Reduce refined carbohydrates and sugary beverages. You don’t need a perfect diet. Meaningful improvement comes from meaningful reduction. Start with the biggest sources first.
• Move after meals. Even a 10-minute walk after eating meaningfully blunts post-meal glucose spikes. This is one of the most efficient blood sugar interventions available and requires no equipment or gym membership.
• Prioritize sleep. Seven to nine hours consistently. If you snore, have been told you stop breathing at night, or wake unrefreshed, ask about sleep apnea testing at your next visit.
• Know all your numbers. A1C, fasting glucose, blood pressure, cholesterol, and kidney function together tell a more complete story than any one of them alone.
• Have a medication review. If you’re already on diabetes medication and your A1C is above target, or if you haven’t discussed GLP-1 agents or SGLT2 inhibitors with your provider, that conversation is overdue.
• Come in. Schedule your annual physical at Altitude Family Medicine — whether it’s been six months or six years. This is manageable. Let’s build the plan.

The Bottom Line

Blood sugar is not just a number on a lab report. It’s a window into how your metabolic system is functioning — and one of the most powerful predictors of whether you’ll develop heart disease, kidney disease, nerve damage, vision loss, cancer, or cognitive decline in the decades ahead.

The single most important thing you can do is show up for your annual physical and get tested comprehensively. Not a basic glucose and a handshake — a real metabolic evaluation that looks for the earliest signals of a problem developing. That’s where we find things in time to change them.

The tools available today — lifestyle programs, GLP-1 medications, SGLT2 inhibitors, continuous glucose monitoring, and individualized lab testing — are more effective than they have ever been. People who engage early and work with a provider on a real plan do substantially better than those who wait for symptoms.

The gap between knowing and doing is where most people get stuck. We’re here to help close that gap.

References

1. American Diabetes Association. Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1).
2. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
4. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
5. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2024. CDC.gov. Accessed June 2026.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352(9131):837–853.
7. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
8. Jiang Y, Ben Q, Shen H, et al. Diabetes mellitus and incidence and mortality of colorectal cancer. Eur J Epidemiol. 2011;26(11):863–876.
9. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239–2251.
10. Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Investig. 2013;4(6):640–650.

This article is for educational purposes and reflects evidence-based guidelines as of 2025. Individual recommendations may vary. Always discuss your specific situation with your healthcare provider.